By recruiting Tregs via CXCL12 and activating stromal stiffening pathways such as VAV2, CAFs reinforce immunosuppression—a mechanism linked to trastuzumab resistance in HER2+ breast cancer (Yang et al., 2016; Kieffer et al., 2020). Here, ERBB2 is linked to breast carcinoma.